Abstract Number: 2134 • 2014 ACR/ARHP Annual Meeting
Baseline Scintigraphic Detection of TNFá As a Predictor of Therapy Response after Treatment with Certolizumab Pegol in Rheumatoid Arthritis and Spondyloarthritis Patients
Background/Purpose: A major challenge in the biologic era is to predict clinical response. A large variability in the level of TNFα expression has been recognized…Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting
Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?
Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…Abstract Number: 2440 • 2013 ACR/ARHP Annual Meeting
Is There a Role For Etoricoxib In Patients With Axial Ankylosing spondylitis Refractory To Traditional NSAID?
Background/Purpose: Anti-TNF treatment has demonstrated its effectiveness in axial ankylosing spondylitis (AS) patients with inadecuate response to traditional NSAIDs (tNSAIDs) therapy (>=2 tNSAIDs), but also aspects…Abstract Number: 1556 • 2013 ACR/ARHP Annual Meeting
Paradoxical Psoriasis: Experience Of a Biological Therapy Monographic Unit
Background/Purpose: Anti TNF therapy’s efficacy in controlling cutaneous psoriasis has widely been proven, but development of paradoxical psoriasis (PPs) as a side effect can occur.…Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…Abstract Number: 2380 • 2013 ACR/ARHP Annual Meeting
Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?
Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for…Abstract Number: 1529 • 2013 ACR/ARHP Annual Meeting
Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Background/Purpose: Efficacy of TNF alpha inhibitors (TNFi) has been clearly established in patients with axial SpondyloArthritis (ax-SpA), but its effectiveness and adherence with regard to…Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting
Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Background/Purpose: Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell…Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting
Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…Abstract Number: 1532 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis
Background/Purpose: Radiography of the sacroiliac joints (SIJ) in spondyloarthritis (SpA) is a valuable diagnostic tool but is unreliable and unresponsive for assessment of treatment effects.…Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…Abstract Number: 2339 • 2013 ACR/ARHP Annual Meeting
Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect®) For Treatment Of Rheumatoid Arthritis
Background/Purpose: Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional…Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 29
- Next Page »